IDRSF (Idorsia) FFO


IDRSF Idorsia Ltd IDRSF
59 GF Score
Price $7.40
GF Value $3.37
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Idorsia FFO?

FFO (Funds from operations) only applies to REITs.

IDRSF
59GF Score
Idorsia Ltd IDRSF
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Idorsia (IDRSF) Overvalued in 2026?

Based on GuruFocus' analysis, Idorsia stock appears to be overvalued. The current stock price of $7.40 is trading 119.6% above its estimated GF Value™ of $3.37. GuruFocus considers Idorsia to be Significantly Overvalued.

Key valuation signals for IDRSF:

  • FFO:
  • GF Value™: $3.37 vs. price of $7.40 (119.6% above fair value)
  • GF Score™: 59/100 with 3 warning signs

No single metric tells the full story. See the IDRSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Idorsia Business Description

Address Hegenheimermattweg 91, Allschwil, CHE, 4123
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. The company is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide new therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. The company's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.
59GF Score

Get the complete analysis for IDRSF

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.40
Price
$3.37
GF Value